NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways

Alex To, Ryohichi Sugimura · 2025

Read NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways by Alex To, Ryohichi Sugimura (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742054.txt.

Description

To and Sugimura explain how a new cancer drug candidate releases a brake on T cells in twenty twenty-five. A protein called Cbl-b normally restrains immune cell activation. Mice lacking it reject tumors yet show only mild autoimmunity. The drug NX-1607 blocks Cbl-b and is in early human trials.

The commentary reviews a screen that combined the drug with eighty-one other inhibitors. Blocking the MAPK and ERK signaling route erased the drug's boost to T cells. Blocking a related kinase family also weakened activation markers. In a mouse lymphoma model, the drug raised activity along that same route. The findings map the PLC gamma one to MAPK and ERK axis. That map should guide development of the immunotherapy.

Catalog record

CREATORAlex To, Ryohichi Sugimura
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE11 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12742054

Browse the full library · About the Tower of Babel